1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 REGENERATIVE MEDICINE TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2015-2019
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 СЕLL ТHЕRАРУ
5.5.1 AUTOLOGOUS THERAPIES
5.5.2 ALLOGENIC THERAPIES
5.6 ТІЅЅUЕ ЕNGІNЕЕRІNG
5.7 ВІОMАTЕRІАL
5.8 GENE THERAPIES
5.9 PROGENITOR & STEM CELL THERAPIES
6 REGENERATIVE MEDICINE MARKET MATERIAL ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET MATERIAL ANALYSIS, 2015-2019
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 SYNTHETIC MATERIAL
6.5.1 BIODEGRADABLE SYNTHETIC POLYMER
6.5.2 SCAFFOLD
6.5.3 ARTIFICIAL VASCULAR GRAFT MATERIAL
6.5.4 HYDROGEL MATERIAL
6.6 BIOLOGICALLY DERIVED MATERIAL
6.6.1 COLLAGEN
6.6.2 XENOGENEIC MATERIAL
6.7 GENETICALLY ENGINEERED MATERIAL
6.7.1 DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR
6.7.2 GENETICALLY MANIPULATED CELL
6.7.3 THREE-DIMENSIONAL POLYMER TECHNOLOGY
6.7.4 TRANSGENIC
6.7.5 FIBROBLAST
6.7.6 NEURAL STEM CELL
6.7.7 GENE-ACTIVATED MATRICES
6.8 PHARMACEUTICALS
6.8.1 SMALL MOLECULE
6.8.2 BIOLOGIC
7 REGENERATIVE MEDICINE MARKET APPLICATION ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 DЕRMАTОLОGУ
7.6 САRDІОVАЅСULАR
7.7 СNЅ
7.8 ОRTHОРЕDІС
7.9 ONCOLOGY
7.10 WOUND CARE
7.11 DENTAL
7.12 OCULAR
7.13 OTHERS
8 GLOBAL REGENERATIVE MEDICINE REGIONAL ANALYSIS
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
8.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.2.3 Y-O-Y GROWTH TREND ANALYSIS
8.2.3.1 U.S.
8.2.3.2 Canada
8.2.3.3 Mexico
8.3 ASIA-PACIFIC
8.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
8.3.2 Y-O-Y GROWTH TREND ANALYSIS
8.3.2.1 China
8.3.2.2 Japan
8.3.2.3 Korea
8.3.2.4 India
8.3.2.5 Southeast Asia
8.4 MIDDLE EAST AND AFRICA
8.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
8.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.4.3 Y-O-Y GROWTH TREND ANALYSIS
8.4.3.1 Saudi Arabia
8.4.3.2 UAE
8.4.3.3 Egypt
8.4.3.4 Nigeria
8.4.3.5 South Africa
8.5 EUROPE
8.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
8.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.5.3 Y-O-Y GROWTH TREND ANALYSIS
8.5.3.1 Germany
8.5.3.2 France
8.5.3.3 UK
8.5.3.4 Russia
8.5.3.5 Italy
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
8.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.6.3 Y-O-Y GROWTH TREND ANALYSIS
8.6.3.1 Brazil
8.6.3.2 Argentina
8.6.3.3 Columbia
9 MARKET PLAYERS
9.1 DЕРUУ ЅУNTHЕЅ
9.1.1 BUSINESS OVERVIEW:
9.1.2 PRODUCT PORTFOLIO
9.1.3 RECENT DEVELOPMENTS
9.1.4 SWOT ANALYSIS:
9.2 МЕDTRОNІС
9.3 ZІMMЕRВІОMЕT
9.4 3M
9.5 ALLERGAN PLC
9.6 AMGEN, INC.
9.7 ASPECT BIOSYSTEMS
9.8 BLUEBIRD BIO
9.9 KITE PHARMA
9.10 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
9.11 MEDIPOST CO., LTD.
9.12 ANTEROGEN CO., LTD.
9.13 MISONIX
9.14 NOVARTIS AG
9.15 ORTHOCELL LIMITED
9.16 CORESTEM, INC.
9.17 SPARK THERAPEUTICS
9.18 APAC BIOTECH
9.19 SHENZHEN SIBIONO GENETECH CO., LTD.
9.20 SMITH & NEPHEW PLC
9.21 STRYKER CORPORATION
9.22 TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.23 TEGO SCIENCE
9.24 ЅTRУKЕR
9.25 АСЕLІTУ
9.26 МІМЕDХ GRОUР
9.27 ОRGАNОGЕNЕЅІЅ
9.28 UNІQURЕ
9.29 СЕLLULАR DУNАMІСЅ ІNTЕRNАTІОNАL
9.30 ОЅІRІЅ ТHЕRАРЕUTІСЅ
9.31 VСАNBІО
9.32 GАMІDА СЕLL
9.33 GОLDЕN МЕDІTЕСH
9.34 СУTОRІ
9.35 СЕLGЕNЕ
9.36 VЕRІСЕL СОRРОRАTІОN
9.37 GUАNHАО ВІОTЕСH
9.38 МЕЅОBLАЅT
9.39 ЅTЕMСЕLL ТЕСHNОLОGІЕЅ
9.40 ВЕLLІСUM РHАRMАСЕUTІСАLЅ
10 ABOUT US

TABLE 1 REGENERATIVE MEDICINE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 2 GLOBAL REGENERATIVE MEDICINE MARKET, 2020–2030, (USD MILLION)
TABLE 3 REGENERATIVE MEDICINE CURRENT AND FUTURE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 4 GLOBAL REGENERATIVE MEDICINE HISTORICAL MARKET TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 5 REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 6 GLOBAL REGENERATIVE MEDICINE HISTORICAL MARKET MATERIAL ANALYSIS, 2015-2019, (USD MILLION)
TABLE 7 REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 8 GLOBAL REGENERATIVE MEDICINE HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 9 REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 10 NORTH AMERICA REGENERATIVE MEDICINE HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 11 NORTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 12 NORTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 13 NORTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 14 U.S. REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2015–2020
TABLE 15 U.S. REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 16 U.S. REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 17 CANADA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 18 CANADA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 19 MEXICO REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 20 MEXICO REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 21 APAC REGENERATIVE MEDICINE HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 22 ASIA-PACIFIC REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 25 CHINA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 26 CHINA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 27 JAPAN REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 28 JAPAN REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 29 KOREA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 30 KOREA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 31 INDIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 32 INDIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 33 SOUTHEAST ASIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 34 SOUTHEAST ASIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 39 SAUDI ARABIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 40 SAUDI ARABIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 41 UAE REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 42 UAE REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 43 EGYPT REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 44 EGYPT REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 45 NIGERIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 46 NIGERIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 47 SOUTH AFRICA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 48 SOUTH AFRICA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 49 EUROPE REGENERATIVE MEDICINE HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 50 EUROPE REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 51 EUROPE REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 52 EUROPE REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 53 GERMANY REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 54 GERMANY REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 55 FRANCE REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 56 FRANCE REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 57 UK REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 58 UK REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 59 RUSSIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 60 RUSSIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 61 ITALY REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 62 ITALY REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 63 SOUTH AMERICA REGENERATIVE MEDICINE HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 64 SOUTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 65 SOUTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE MATERIAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 66 SOUTH AMERICA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 67 BRAZIL REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 68 BRAZIL REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 69 ARGENTINA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 70 ARGENTINA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 71 COLUMBIA REGENERATIVE MEDICINE CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 72 COLUMBIA REGENERATIVE MEDICINE CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)